3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
59
Neoplasm Metastasis
24
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Adenocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Salivary Gland Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Solid Cancer
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Fluorouracil
267
Oxaliplatin
266
Capecitabine
225
Leucovorin
209
Irinotecan
151
Radiotherapy
132
Bevacizumab
112
Cetuximab
81
Folfox protocol
49
Surgical Procedures, Operative
44
Radiation
41
Drug Therapy
41
Neoadjuvant Therapy
40
Chemoradiotherapy
33
Chemotherapy, Adjuvant
32
Panitumumab
27
XELOX
25
Magnetic Resonance Spectroscopy
22
Radiotherapy, Intensity-Modulated
21
Floxuridine
17
Biopsy
16
Nivolumab
15
Gemcitabine
15
Early Intervention, Educational
15
pembrolizumab
14
Laparoscopy
14
IFL protocol
14
Celecoxib
14
trifluridine tipiracil drug combination
13
Gene Expression Profiling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rectal Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07407465
2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
42 enrolled